Is this your firm? Get featured or correct your listing →
Recent changes
- Jun 30, 2026Jun 30, 2026Invested in Flare Therapeutics (Series C, $85M) GlobeNewswire
Portfolio
1 totalRecent Investment Activity
1Track record: led 0 and participated in 1 of 1 tracked venture round · 1 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Flare Therapeutics | Series C | Participated | $85M | — | Pulse story |
Co-Investors
8Similar Firms
overlapping sector, stage or regionValue Add Research
Latest Pulse
- Oct 13, 2026TRexBio Closes $116.7M IPO, Lilly Eyes Bigger StakeTRexBio closed its IPO on Oct. 13, selling 8.33 million shares at $14 for about $116.7 million, with largest shareholder Eli Lilly signaling interest in raising its stake.→
- Jun 30, 2026Flare Therapeutics Raises $85M, Names New CEOFlare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.→
Pfizer Ventures FAQ
What companies has Pfizer Ventures invested in?
Pfizer Ventures' portfolio includes Flare Therapeutics.
Who does Pfizer Ventures co-invest with most?
In the rounds Value Add tracks, Pfizer Ventures most often invests alongside Boxer Capital (1 shared deal), Casdin Capital (1 shared deal), Eli Lilly (1 shared deal), Eli Lilly and Company (1 shared deal), GordonMD Global Investments (1 shared deal).
Sources & methodologyshow
Where these figures come from
- GlobeNewswireprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.